Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 1, 2012, Pages 47-58

  Aparo, Santiago ^a   Goel, Sanjay ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Colorectal neoplasms; Neoplasm metastasis; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CRIZOTINIB; FIRTECAN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LENALIDOMIDE; OXALIPLATIN; PANITUMUMAB;

ACNE; AREA UNDER THE CURVE; ASTHENIA; BLEEDING DISORDER; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL EFFECTIVENESS; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG INDICATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TRANSFORMATION; DYSPNEA; EVIDENCE BASED MEDICINE; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERPIGMENTATION; HYPERTENSION; HYPOMAGNESEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRITIS; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; RASH; RECOMMENDED DRUG DOSE; REVIEW; SKIN ATROPHY; STOMATITIS; TREATMENT DURATION; TREATMENT PLANNING; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLONIC NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; EARLY DIAGNOSIS; HUMANS; LYMPHATIC METASTASIS; MOLECULAR TARGETED THERAPY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862132933     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.08.006     Document Type: Review

References (61)

1. Gunderson L.L., Jessup J.M., Sargent D.J., et al. Revised TN categorization for colon cancer based on National survival outcomes data. J Clin Oncol 2010, 28(2):264-271.
2. Altekruse SF. SEER cancer statistics review, 1975-2007, National Cancer Institute, Bethesda, MD. Available from: ; 2007 [accessed 15.10.10]. http://seer.cancer.gov/csr/1975_2007.
3. The Meta-analysis Group in Cancer Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998, 16(1):301-308.
4. The Meta-analysis Group In Cancer Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004, 22(18):3766-3775.
5. Saltz L.B., Clarke S., Díaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26(12):2013-2019.
6. Clinical Practice Guidelines in Oncology. Available from: ; September 10, 2010 [accessed 10.10.10]. http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf.
7. Floyd J., Mirza I., Sachs B., et al. Hepatotoxicity of chemotherapy. Semin Oncol 2006, 33(1):50-67.
8. Koren G., Beatty K., Seto A., et al. The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 1992, 26(3):363-3071.
9. Rothenberg M.L., Oza A.M., Bigelow R.H., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003, 21(11):2059-2069.
10. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18(16):2938-2947.
11. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22(1):23-30.
12. Colucci G., Gebbia V., Paoletti G., et al. Phase III randomized trial of folfiri versus folfox4 in the treatment of advanced colorectal cancer: a multicenter study of the gruppo oncologico dell'italia meridionale. J Clin Oncol 2005, 23(22):4866-4875.
13. Cunningham D., Pyrhönen S., James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352(9138):1413-1418.
14. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000, 343(13):905-914.
15. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355(9209):1041-1047.
16. Díaz-Rubio E., Tabernero J., Gómez-España A., et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the spanish cooperative group for the treatment of digestive tumors trial. J Clin Oncol 2007, 25(27):4224-4230.
17. Cassidy J., Clarke S., Diaz-Rubio E., et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008, 26(12):2006-2012.
18. Porschen R., Arkenau H.-T., Kubicka S., et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the aio colorectal study group. J Clin Oncol 2007, 25(27):4217-4223.
19. Ducreux M., Bennouna J., Hebbar M., et al. Efficacy and safety findings from a randomized phase III study of capecitabine (X)+oxaliplatin (O) (XELOX) vs. infusional 5-FU/LV+(FOLFOX-6) for metastatic colorectal cancer (MCRC). 2007 ASCO annual meeting 2007, Abstract No: 4029.
20. Avastin product information. Available from: [accessed 28.05.11]. http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf.
21. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342.
22. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (folfox4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study e3200. J Clin Oncol 2007, 25(12):1539-1544.
23. Ziras N., Polyzos A., Kakolyris S., et al. CAPIRI (capecitabine, irinotecan)+bevacizumab vs FOLFIRI (folinic acid, 5 fluorouracil, irinotecan)+bevacizumab for the treatment of patients with metastatic colorectal cancer (mCRC): Interim analysis for safety of a randomized phase III trial. 2008 ASCO annual meeting 2008, Abstract No: 15008.
24. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351(4):337-345.
25. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357(20):2040-2048.
26. Van Cutsem E., Nowacki M., Lang I., et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. 2007 ASCO annual meeting 2007, Abstract No: 4000.
27. Van Cutsem E., Lang I., Folprecht G., et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial. 2010 gastrointestinal cancers symposium 2010, Abstract No: 281.
28. Bokemeyer C., Kohne C., Rougier P., et al. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. 2010 ASCO annual meeting 2010, Abstract No: 3506.
29. Loupakis F., Pollina L., Stasi I., et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009, 27(16):2622-2629.
30. Lièvre A., Bachet J.-B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26(3):374-379.
31. Laurent-Puig P., Cayre A., Manceau G., et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type kras metastatic colon cancer. J Clin Oncol 2009, 27(35):5924-5930.
32. Sobrero A.F., Maurel J., Fehrenbacher L., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(14):2311-2319.
33. Chung K.Y., Shia J., Kemeny N.E., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistichemistry. J Clin Oncol 2005, 23(9):1803-1810.
34. Gravalos C., Javier Cassinello J., Pilar García-Alfonso P., et al. Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol 2010, 74:16-26.
35. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25(13):1658-1664.
36. Douillard J., Siena S., Cassidy J., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (folfox4) versus folfox4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME Study. J Clin Oncol 2010, 28(31):4697-4705.
37. Peeters M., Price T.J., Cervantes A., et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (folfiri) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28(31):4706-4712.
38. Munoz Llarena A., Salud Salvia A., García Girón C., et al. Randomized phase III trial, with irinotecan and capecitabine (XELIRI) versus irinotecan, 5FU and folinic acid (Saltz regimen) in first-line treatment on metastatic colorectal cancer patients (CRC). 2008 gastrointestinal cancers symposium 2008, Abstract No: 379.
39. Cassidy J., Clarke S., Diaz-Rubio E., et al. XELOX-1/NO16966, a randomized phase III trial of first-line XELOX compared with FOLFOX4 for patients with metastatic colorectal cancer (MCRC): updated survival and tolerability results. 2009 gastrointestinal cancers symposium 2009, Abstract No: 382.
40. Zafar S.Y., Marcello J.E., Wheeler J.L., et al. Longitudinal patterns of chemotherapy use in metastatic colorectal cancer. J Oncol Pract 2009, 5(5):228-233.
41. Allegra C.J., Jessup J.M., Somerfield M.R., et al. American society of clinical oncology provisional clinical opinion: testing for kras gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27(12):2091-2096.
42. Grothey A., Sugrue M.M., Purdie D.M., et al. Bevacizumab beyond first progression is associated with prolongued overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). Clin Oncol 2008, 26(33):5326-5334.
43. Tournigand C., André T., Achille E., et al. FOLFIRI Followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22(2):229-237.
44. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006, 24(3):394-400.
45. Chibaudel B., Maindrault-Goebel F., Lledo G., et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol 2009, 27(34):5727-5733.
46. Nordlinger B., Guiguet M., Vaillant J.C., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996, 77(7):1254-1262.
47. Kemeny N., Huang Y., Cohen A.M., et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999, 341(27):2039-2048.
48. Kemeny M.M., Adak S., Gray B., et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002, 20(6):1499-1505.
49. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371(9617):1007-1016.
50. Bathe O.F., Ernst S., Sutherland F.R., et al. A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer 2009, 9:156.
51. Gruenberger B., Tamandl D., Schueller J., et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008, 26(11):1830-1835.
52. Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (folfoxiri) compared with infusional fluorouracil, leucovorin, and irinotecan (folfiri) as first-line treatment for metastatic colorectal cancer: the gruppo oncologico nord ovest. J Clin Oncol 2007, 25(13):1670-1676.
53. Masi G., Loupakis F., Pollina L., et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009, 249(3):420-425.
54. Prevett M.C., Hooper A.T., Bassi R., et al. Enhanced antitumor activity of antiepidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002, 8:994-1003.
55. Vauthey J.N., Pawlik T.M., Rivero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006, 24(13):2065-2072.
56. Fernandez F.G., Ritter J., Goodwin J.W., et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005, 200:845-853.
57. US: National Institutes of Health. Available from: ; October 5, 2010 [accessed 15.10.10]. http://clinicaltrials.gov/ct2/show/NCT00803647%3Fterm=cetuximab+AND+colon+AND+metastatic+liver%26rank=10.
58. US: National Institutes of Health. Available from: ; August 10, 2010 [accessed 15.10.10]. http://clinicaltrials.gov/ct2/show/NCT01032291%3Fterm=colon+Kras+mutant%26rank=3.
59. US: National Institutes of Health. Available from: ; March 30, 2010 [accessed 15.10.10]. http://clinicaltrials.gov/ct2/show/NCT00912327%3Fterm=colon+Kras+mutant%26rank=9.
60. ®, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 2010, 28:641-649.
61. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703.